Analysts at Stephens began coverage on shares of Thermo Fisher Scientific (NYSE:TMO – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The firm set an “overweight” rating and a $680.00 price target on the medical research company’s stock. Stephens’ price objective points to a potential upside of 10.95% from the company’s current price.
Several other analysts also recently weighed in on TMO. TD Cowen lifted their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Jefferies Financial Group reiterated a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Barclays dropped their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. JPMorgan Chase & Co. upped their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Finally, Morgan Stanley upped their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $653.72.
View Our Latest Stock Report on TMO
Thermo Fisher Scientific Price Performance
Shares of TMO stock traded down $5.66 during trading hours on Tuesday, hitting $612.92. The stock had a trading volume of 1,169,195 shares, compared to its average volume of 1,484,266. Thermo Fisher Scientific has a one year low of $415.60 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The stock’s 50-day moving average price is $608.74 and its two-hundred day moving average price is $582.32. The stock has a market capitalization of $234.13 billion, a price-to-earnings ratio of 39.31, a PEG ratio of 3.90 and a beta of 0.78.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the business posted $5.15 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific will post 21.72 EPS for the current year.
Insider Activity
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The disclosure for this sale can be found here. Insiders sold 23,084 shares of company stock valued at $14,094,292 in the last ninety days. Company insiders own 0.34% of the company’s stock.
Institutional Trading of Thermo Fisher Scientific
Large investors have recently added to or reduced their stakes in the company. Mattson Financial Services LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $1,078,000. Centaurus Financial Inc. lifted its stake in shares of Thermo Fisher Scientific by 3.3% during the 2nd quarter. Centaurus Financial Inc. now owns 6,283 shares of the medical research company’s stock worth $3,475,000 after buying an additional 201 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 68,321 shares of the medical research company’s stock worth $37,782,000 after buying an additional 264 shares during the last quarter. Heritage Wealth Management Inc. acquired a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $334,000. Finally, Sanctuary Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $31,573,000. 89.23% of the stock is owned by institutional investors.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
- Five stocks we like better than Thermo Fisher Scientific
- Insider Trades May Not Tell You What You Think
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Should you invest $1,000 in Thermo Fisher Scientific right now?
Before you consider Thermo Fisher Scientific, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Thermo Fisher Scientific wasn’t on the list.
While Thermo Fisher Scientific currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
